Baxter International, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Directors for upcoming cardiovascular device business spin-off in mid-2000 includes Michael Mussallem, who will be CEO and chairman of the new company. He has served as a group VP at Baxter since 1994. Also joining the board are Vernon Loucks, Baxter's current chairman, Avery Dennison Corp. President and CEO Philip Neal, and David Pyott, President and CEO of Allergan, Inc. The new company will have annual sales of approximately $900 mil